Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude visant à évaluer l'innocuité et la pharmacocinétique de l'AZD7760 chez des adultes en bonne santé (phase I) et des adultes atteints d'insuffisance rénale terminale sous hémodialyse avec un cathéter veineux central (phase IIa) (PEAK)

27 octobre 2026 mis à jour par: AstraZeneca

Une étude de phase I/IIa randomisée, en double aveugle et contrôlée par placebo pour évaluer l'innocuité et la pharmacocinétique de l'AZD7760 chez des participants en bonne santé et chez des patients atteints d'insuffisance rénale terminale recevant une hémodialyse via un cathéter veineux central

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Description détaillée

In the Phase I portion of the study, participants will be randomized to receive one of 3 dosages of AZD7760 or placebo as a single intravenous infusion.

Study details include:

  • A 28-day Screening Period.
  • A Dosing Period of 3 days in which a single intravenous infusion will be given on Day 1.
  • A Follow-up Period of 12 months from the time of administration of the study intervention.

In the Phase IIa portion of the study, participants will be randomized to receive either AZD7760 or placebo as 2 intravenous infusions given 3 months apart.

Study details include:

  • A 28-day Screening Period.
  • A Dosing Period in which 2 intravenous infusions will be given 3 months apart (Day 1 and Day 91).
  • A Follow-up Period of 12 months after the last administration of the study intervention on Day 91.

Type d'étude

Interventionnel

Inscription (Réel)

242

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alabama
      • Huntsville, Alabama, États-Unis, 35805
        • Research Site
    • California
      • Chula Vista, California, États-Unis, 91910
        • Research Site
      • Glendale, California, États-Unis, 91206
        • Research Site
      • Granada Hills, California, États-Unis, 91344
        • Research Site
      • Los Angeles, California, États-Unis, 90027
        • Research Site
      • Northridge, California, États-Unis, 91324
        • Research Site
      • Northridge, California, États-Unis, 91325
        • Research Site
      • Oxnard, California, États-Unis, 93036
        • Research Site
      • Riverside, California, États-Unis, 92503
        • Research Site
      • San Dimas, California, États-Unis, 91773
        • Research Site
      • Tarzana, California, États-Unis, 91356
        • Research Site
      • Valencia, California, États-Unis, 91355
        • Research Site
      • Victorville, California, États-Unis, 92392
        • Research Site
    • Colorado
      • Englewood, Colorado, États-Unis, 80110
        • Research Site
    • Florida
      • Bradenton, Florida, États-Unis, 34209
        • Research Site
      • Coral Springs, Florida, États-Unis, 33071
        • Research Site
      • Hollywood, Florida, États-Unis, 33024
        • Research Site
      • Orlando, Florida, États-Unis, 32806
        • Research Site
      • Tampa, Florida, États-Unis, 33603
        • Research Site
    • Georgia
      • Lawrenceville, Georgia, États-Unis, 30046
        • Research Site
    • Illinois
      • Chicago, Illinois, États-Unis, 60640
        • Research Site
      • Chicago, Illinois, États-Unis, 60643
        • Research Site
    • Iowa
      • Iowa City, Iowa, États-Unis, 52242
        • Research Site
    • Kentucky
      • Lexington, Kentucky, États-Unis, 40503
        • Research Site
    • Maryland
      • Baltimore, Maryland, États-Unis, 21225
        • Research Site
    • Michigan
      • Detroit, Michigan, États-Unis, 48202
        • Research Site
      • Pontiac, Michigan, États-Unis, 48341
        • Research Site
    • Mississippi
      • Tupelo, Mississippi, États-Unis, 38801
        • Research Site
    • Missouri
      • Kansas City, Missouri, États-Unis, 64111
        • Research Site
    • Nebraska
      • Lincoln, Nebraska, États-Unis, 68510
        • Research Site
    • Nevada
      • Las Vegas, Nevada, États-Unis, 89128
        • Research Site
    • New Jersey
      • Jersey City, New Jersey, États-Unis, 07305
        • Research Site
    • New Mexico
      • Albuquerque, New Mexico, États-Unis, 87109
        • Research Site
    • New York
      • Ridgewood, New York, États-Unis, 11385
        • Research Site
    • North Carolina
      • Winston-Salem, North Carolina, États-Unis, 27103
        • Research Site
    • Pennsylvania
      • Bethlehem, Pennsylvania, États-Unis, 18017
        • Research Site
    • Texas
      • Beaumont, Texas, États-Unis, 77706
        • Research Site
      • Dallas, Texas, États-Unis, 75246
        • Research Site
      • Houston, Texas, États-Unis, 77074
        • Research Site
      • McAllen, Texas, États-Unis, 78503
        • Research Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 55 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Phase I:

  • Participant must be 18 to 55 years of age (inclusive), at the time of signing the informed consent.
  • Body weight ≥ 45 kilograms (kg) and ≤ 110 kg and Body Mass Index (BMI) within the range ≥ 18.0 to ≤ 30.0 kilograms per square meter (kg/m2) (inclusive) at screening.
  • Healthy participants with no clinically significant concomitant diseases or medications (except for those specifically permitted by the protocol) according to medical history, physical examination, screening safety laboratory tests, and screening parameters, as per the judgement of the investigator.

Phase IIa:

  • Participant must be ≥ 18 years of age at the time of signing the informed consent.

  • Participants who meet all of the following disease status requirements:

    1. Diagnosed with End-stage kidney disease (ESKD).
    2. Requiring hemodialysis through a tunneled central venous catheter as the primary vascular access for hemodialysis.
    3. Receiving hemodialysis for treatment of ESKD for at least 60 days before randomization.
    4. At least 3 previous dialysis sessions using current dialyzer.
    5. Receiving adequate hemodialysis based on a single-pool Kt/V measurement > 1.2 within the last 30 days.
    6. No new medications have been added to the participant's regimen in the last 2 weeks prior to dosing. 'New medication' is defined as any medication that has not been prescribed or used by the participant previously (including formulation changes). Medication previously prescribed or used by the participant with dose adjustments is allowed and not considered as new medication for the purpose of this study.
    7. Not taking long-term systemic antibiotics with activity against S aureus.

Exclusion Criteria:

Phase I:

  • Known hypersensitivity to any component of the study intervention
  • Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal antibodies (mAbs).
  • Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
  • Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) above 1.5 × upper limit of normal (ULN) at screening. Testing may be repeated once at the investigator's discretion.
  • Estimated glomerular filtration rate < 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at screening.
  • Hemoglobin or platelet count below the lower limit of normal at screening. Testing may be repeated once at the investigator's discretion.
  • White blood cell counts outside normal reference ranges unless judged by the investigator to be out of range given the known variation in white blood cell count reference interval by ethnicity. Testing may be repeated once at the investigator's discretion.
  • History of malignancy other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years.
  • Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results. Testing may be repeated once at the investigator's discretion.
  • Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening, as judged by the investigator.
  • Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior to or on day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the 28-day Screening Period or may be rescreened once.
  • Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.
  • Any condition that has the potential to increase clearance of the study intervention (eg, protein loss conditions such as severe enteropathies, or plasmapheresis).
  • Blood drawn in excess of a total of 450 milliliters (mL) (1 unit) for any reason within 2 months prior to screening.
  • Absence of suitable veins for blood sampling and administration of study intervention.
  • Any other condition that would compromise safety of the participants.
  • Any condition that, in the opinion of the investigator, might interfere with evaluation of the study intervention or interpretation of participant safety or study results.

Phase IIa:

  • Known hypersensitivity to any component of the study intervention.

  • History of allergic disease or reactions likely to be exacerbated by any component of the study intervention as listed in dose formulation section.

  • Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.

  • Hemoglobin < 9 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.

  • Serum albumin of < 3 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.

  • Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (eg, deep vein thrombosis or pulmonary embolism, but excluding vascular access thrombosis) within 90 days prior to randomization.

  • Known S aureus infection within 90 days of study entry.

  • Known acute viral or bacterial infection or symptoms/signs consistent with such an infection within the 21 days prior to infusion or study intervention. Mild intercurrent viral illness with a temperature of 38.1 °C (100.6 °F) or less does not require exclusion, if in the judgement of the investigator this illness will not interfere with the evaluation of the mAb.

  • Participants with malignancy undergoing chemotherapy.

  • Scheduled date for living donor kidney transplant.

  • Plans to switch to peritoneal dialysis within the primary endpoint time period (181 days).

  • Regarding arteriovenous fistula (AVF) or arteriovenous graft (AVG):

    (a) Future AVG or AVG: (i) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG use within 90 days of randomization are not eligible.

(ii) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG placement, but no plans for AVF or AVG use within 90 days of randomization are eligible.

(b) Existing AVG or AVG: (i) Participants with central venous catheters in use for dialysis, but also with an existing AVF or AVG that is not in use and with no future plans for use are eligible.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Phase I: AZD7760 Dose A

Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1.

Participants will receive AZD7760 as a single intravenous infusion.

Expérimental: Phase I: AZD7760 Dose B

Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1.

Participants will receive AZD7760 as a single intravenous infusion.

Expérimental: Phase I: AZD7760 Dose C

Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1.

Participants will receive AZD7760 as a single intravenous infusion.

Comparateur placebo: Phase I: Placebo

Participants will receive a single dose of placebo on Day 1.

Participants will be administered placebo through intravenous infusion.

Expérimental: Phase IIa: AZD7760 Dose D and Placebo

Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91.

Participants will receive AZD7760 as a single intravenous infusion.

Participants will be administered placebo through intravenous infusion.

Expérimental: Phase IIa: AZD7760 Dose E

Participants will receive AZD7760 Dose E on Day 1 and Day 91.

Participants will receive AZD7760 as a single intravenous infusion.

Comparateur placebo: Phase IIa: Placebo

Participants will receive placebo on Day 1 and on Day 91.

Participants will be administered placebo through intravenous infusion.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Phase I: Occurence of adverse events (AEs)
Délai: Day 1 to Day 181

To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C.

Day 1 to Day 181
Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
Délai: Day 1 to Day 361

To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C.

Day 1 to Day 361
Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs
Délai: Day 1 to Day 181

To evaluate the safety of AZD7760 compared with placebo as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Phase I: Maximum observed plasma (peak) drug concentration (Cmax)
Délai: Day 1 to Day 361

To characterize the pharmacokinetics (PK) of AZD7760 in serum.

Day 1 to Day 361
Phase I: Time to reach peak or maximum observed concentration following drug administration (tmax)
Délai: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)
Délai: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
Délai: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf)
Délai: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Apparent volume of distribution at steady state (Vss)
Délai: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Apparent volume of distribution at the terminal phase (Vz)
Délai: Day 1 to Day 361

To characterize the PK of AZD7760 in serum.

Day 1 to Day 361
Phase I: Incidence of ADA
Délai: Day 1 to Day 361

To evaluate ADA responses to AZD7760 in serum.

Day 1 to Day 361
Phase IIa: Cmax
Délai: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: tmax
Délai: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: t1/2λz
Délai: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: AUClast
Délai: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: AUCinf
Délai: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Vss
Délai: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Vz
Délai: Day 1 to Day 181 and Day 1 to Day 451

To characterize the serum PK profiles of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Incidence of anti-drug antibodies (ADAs) to AZD7760 in serum
Délai: Day 1 to Day 181 and Day 1 to Day 451

To evaluate ADA responses to AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Occurrence of AEs
Délai: Day 1 to Day 181

To evaluate the safety to Day 181 of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 181
Phase IIa: Occurrence of MAAEs, SAEs, and AESIs
Délai: Day 1 to Day 451

To evaluate the safety to Day 451 of AZD7760 administered as:

  • A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91)
  • 2 IV doses (at Day 1 and Day 91) of Dose E
Day 1 to Day 451

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 décembre 2024

Achèvement primaire (Estimé)

8 mars 2027

Achèvement de l'étude (Estimé)

13 décembre 2027

Dates d'inscription aux études

Première soumission

23 décembre 2024

Première soumission répondant aux critères de contrôle qualité

23 décembre 2024

Première publication (Réel)

27 décembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Délai de partage IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Critères d'accès au partage IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner